Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:38 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,419 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active capsule Clear all
Completed Phase 3 Interventional Results available

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

NCT00537394
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Raltegravir, Darunavir, Tipranavir, Etravirine, Maraviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
61
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 3 Interventional

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

NCT00389779
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
87
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 1Phase 2 Interventional

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

NCT00302744
View directory record Official record
Conditions
Anxiety
Interventions
Psilocybin (drug), Niacin, MRI
Drug · Other · Diagnostic Test
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Nov 2, 2026, 10:38 AM EST
Completed Not applicable Interventional Results available

Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity

NCT01065571
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
carrageenan, dietary intervention with no-carrageenan diet
Dietary Supplement · Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02187471
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits

NCT01399827
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Interventions
ADHD Medication, Omega-3 Fatty Acids
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents

NCT01033383
View directory record Official record
Conditions
Bacteriuria
Interventions
Placebo, Cranberry Capsule
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
65 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
14
States / cities
Bridgeport, Connecticut • Bristol, Connecticut • Fairfield, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Nov 2, 2026, 10:38 AM EST
Completed Not applicable Interventional

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss

NCT04450602
View directory record Official record
Conditions
Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions
ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment)
Dietary Supplement · Other
Lead sponsor
Arbor Life Labs
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Nov 2, 2026, 10:38 AM EST
Not yet recruiting Phase 1Phase 2 Interventional

Sonication-based OCD Neurosurgical Intervention Via Capsulotomy

NCT06131502
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Palo Alto, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IMProving Executive Function Study

NCT03187353
View directory record Official record
Conditions
Cognitive Impairment, RRSO
Interventions
Lisdexamfetamine, Placebo oral capsule
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
35 Years to 58 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 2, 2026, 10:38 AM EST
Recruiting Not applicable Interventional

NT-II™ Collagen for Joint Discomfort and Function

NCT07119645
View directory record Official record
Conditions
Activity-Related Knee Discomfort, Joint Discomfort, Functional Joint Pain, Functional Knee Pain, Knee Acute and Chronic Pain
Interventions
NT-II™ (240 mg), NT-II™ 480 mg, Glucosamine/Chondroitin
Dietary Supplement
Lead sponsor
Hofseth Biocare ASA
Industry
Eligibility
20 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 2 Interventional Results available

Ramelteon in the Prevention of Post-operative Delirium

NCT02324153
View directory record Official record
Conditions
Delirium, Delirium, Dementia, Amnestic, Cognitive Disorders, Delayed Emergence From Anesthesia, Cognitive Disorders
Interventions
Ramelteon, Microcrystalline Cellulose, Riboflavin 100 mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Nov 2, 2026, 10:38 AM EST
Recruiting Phase 2 Interventional

Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity

NCT06617312
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Disorder
Interventions
Cytisinicline, Placebo Oral Capsule
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 3 Interventional Results available

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

NCT01980095
View directory record Official record
Conditions
Dyspepsia, Helicobacter Pylori Infection
Interventions
RHB-105, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Anaheim, California • Chino, California • Jupiter, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 2 Interventional Results available

The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

NCT03324581
View directory record Official record
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
OPC-64005, Atomoxetine, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
26
States / cities
Beverly Hills, California • Garden Grove, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Nov 2, 2026, 10:38 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Magnesium Supplement for Sleep Quality in Women With Poor Sleep

NCT07708857
View directory record Official record
Conditions
Sleep Quality
Interventions
Magnesium Breakthrough, Placebo
Dietary Supplement
Lead sponsor
Jacksonville University
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 2, 2026, 10:38 AM EST
Completed Not applicable Interventional Results available

Knotless Suture in Revision Total Joint Arthroplasty

NCT04403919
View directory record Official record
Conditions
Arthroplasty
Interventions
Conventional Closure: Knee, Barbed suture closure: Knee, Conventional Closure: Hip, Barbed suture closure: Hip
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 3 Interventional Results available

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT03618030
View directory record Official record
Conditions
ADHD
Interventions
PRC-063 oral capsules, Placebo oral capsules
Drug
Lead sponsor
Purdue Pharma, Canada
Industry
Eligibility
18 Years to 60 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Nov 2, 2026, 10:38 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

NCT02629692
View directory record Official record
Conditions
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Interventions
Vodobatinib (K0706) capsules
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
8
States / cities
Downey, California • Los Angeles, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 2 Interventional

Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms

NCT01059383
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
VECAM 40/300, Esomeprazole 20 mg
Drug
Lead sponsor
Vecta Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Diego, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Nov 2, 2026, 10:38 AM EST
Terminated Phase 2 Interventional Results available

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

NCT01756053
View directory record Official record
Conditions
Nicotine Addiction
Interventions
ABT-089, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Nov 2, 2026, 10:38 AM EST
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 2, 2026, 10:38 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Eggshell Membrane and Curcumin Extract Supplementation, Separately or Combined, on Recovery From Intense Exercise

NCT07766720
View directory record Official record
Conditions
Exercise-induced Muscle Soreness, Exercise-induced Joint Pain, Exercise-induced Joint Stiffness, Exercise-induced Cartilage Turnover
Interventions
NEM® brand eggshell membrane powder, curQ+® brand highly absorbable curcumin, EM Placebo, Curc Placebo, NEM® plus curQ+® combination
Dietary Supplement
Lead sponsor
ESM Technologies, LLC
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 2, 2026, 10:38 AM EST
Completed Phase 1 Interventional

Phase 1 Safety Testing of SAR405838

NCT01636479
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
SAR405838
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Nov 2, 2026, 10:38 AM EST